# Mirdametinib in Histiocytic Disorders

> **NCT06153173** · PHASE2 · RECRUITING · sponsor: **Children's Hospital Medical Center, Cincinnati** · enrollment: 40 (estimated)

## Conditions studied

- Langerhans Cell Histiocytosis (LCH)
- Juvenile Xanthogranuloma (JXG)
- Rosai-Dorfman Disease (RDD)
- Histiocytic Disorders

## Interventions

- **DRUG:** Mirdametinib

## Key facts

- **NCT ID:** NCT06153173
- **Lead sponsor:** Children's Hospital Medical Center, Cincinnati
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-05
- **Primary completion:** 2030-03
- **Final completion:** 2031-03
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06153173

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06153173, "Mirdametinib in Histiocytic Disorders". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06153173. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*